Clinical Trials Logo

Compartment Syndrome of Leg clinical trials

View clinical trials related to Compartment Syndrome of Leg.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05006417 Terminated - Clinical trials for Compartment Syndrome of Leg

Botox for the Treatment of Recurrent Chronic Exertional Compartment Syndrome

Start date: November 23, 2022
Phase: Phase 4
Study type: Interventional

10 participants with Recurrent Chronic Exertional Compartment Syndrome (R-CECS) will be enrolled in a 6 month study at the University of Wisconsin Hospitals and Clinics to test the hypothesis that injection of Botox into the affected muscle group will alleviate pain associated with R-CECS.

NCT ID: NCT03922139 Terminated - Clinical trials for Compartment Syndrome of Leg

Botox for the Treatment of Chronic Exertional Compartment Syndrome

Start date: October 8, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

After diagnosis of Chronic Exertional Compartment Syndrome (CECS), the participants will be referred to both physical therapy and Botox injection. In physical therapy, the therapist will perform strength measurements of the lower leg (ankle plantarflexion and dorsiflexion) which will be repeated 2 months following the injection. An ultrasound-guided injection of 50 units of Botox will be administered into the tibialis anterior. 25 units will be injected into two different spots in the muscle one being more proximal and the other distal. This will be a one-time injection and will be observed as to how it effects participant symptoms over the next 6 months at either a clinic visit (at 2 months) or telephone call (at 4 and 6 months after injection) via the University of Wisconsin Running Index. Two months following the injection, the participant will undergo repeat measurements of strength using the Kiio Force Sensor. Should potential participants of childbearing potential wish to enroll in the study, a urine pregnancy test will be performed prior to enrollment; participants will not be enrolled if test is positive.